Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 11, 2022

SELL
$3.72 - $9.0 $64,579 - $156,240
-17,360 Closed
0 $0
Q1 2022

May 10, 2024

BUY
$8.19 - $13.89 $142,178 - $241,130
17,360 New
17,360 $150,000
Q1 2022

Jun 20, 2023

BUY
$8.19 - $13.89 $142,178 - $241,130
17,360 New
17,360 $150,000
Q1 2022

Mar 22, 2023

BUY
$8.19 - $13.89 $52,473 - $88,993
6,407 Added 58.5%
17,360 $150,000
Q1 2022

May 12, 2022

BUY
$8.19 - $13.89 $52,473 - $88,993
6,407 Added 58.5%
17,360 $150,000
Q4 2021

Jun 21, 2023

BUY
$12.98 - $29.75 $142,169 - $325,851
10,953 New
10,953 $156,000
Q3 2021

Jun 21, 2023

BUY
$12.13 - $23.82 $132,859 - $260,900
10,953 New
10,953 $240,000
Q2 2021

May 17, 2024

BUY
$8.34 - $14.59 $91,348 - $159,804
10,953 New
10,953 $146,000
Q2 2021

Jun 21, 2023

BUY
$8.34 - $14.59 $91,348 - $159,804
10,953 New
10,953 $146,000
Q2 2021

Mar 22, 2023

BUY
$8.34 - $14.59 $91,348 - $159,804
10,953 New
10,953 $146,000
Q2 2021

Aug 16, 2021

BUY
$8.34 - $14.59 $91,348 - $159,804
10,953 New
10,953 $147,000

Others Institutions Holding ORMP

About ORAMED PHARMACEUTICALS INC.


  • Ticker ORMP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,827,100
  • Market Cap $90.9M
  • Description
  • Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for th...
More about ORMP
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.